Firm recalls one lot (500 cartons) of dornase alfa cystic fibrosis therapy after finding small punctures in some of the ampules upon shipping. Company recalled 23 lots of the drug a year ago due to similar ampule leakage problems, citing packaging defects. Genentech recalled a Pulmozyme lot in February in conjunction with the reorganization of its South San Francisco manufacturing facility following a warning letter (1"The Pink Sheet" Jan. 1, p. 28)
You may also be interested in...
Genentech is reorganizing its manufacturing operations in an attempt to address multiple FDA concerns regarding its South San Francisco, Calif., manufacturing facility following an August inspection, the company said.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials